• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OpGen Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Changes in Control of Registrant, Financial Statements and Exhibits

    8/2/24 5:28:32 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    false 0001293818 0001293818 2024-07-29 2024-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    July 29, 2024
    Date of Report (date of earliest event reported)

     

     

     

    OpGen, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    001-37367

     

    06-1614015

    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
     

    (I.R.S. Employer
    Identification Number)

     

    23219 Stringtown Road, Suite 300, Clarksburg, MD, 20871
    (Address of principal executive offices)(Zip code)

     

    (240) 813-1260
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   OPGN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    On July 31, 2024, David Lazar, the Company’s Chief Executive Officer and Chairman of the Board of Directors (the “Board”), consummated a transaction pursuant to which he sold 550,000 shares of Series E Convertible Preferred Stock (the “Series E Stock”) of OpGen, Inc. (the “Company”) together with his rights to purchase an additional 2,450,000 shares of Series E Stock under that certain Securities Purchase Agreement, dated March 25, 2024, entered into between Mr. Lazar and the Company, to AEI Capital Ltd. (the “Transaction”). In connection with the consummation of Transaction, and as further described in Item 5.02 of this Form 8-K, Mr. Lazar agreed to resign from his positions with the Company and to accept shares of common stock, par value $0.01, of the Company (the “Common Stock”) in lieu of amounts owed by the Company to Mr. Lazar upon his resignation pursuant to his Employment Agreement, dated April 11, 2024, with the Company, and his Director Agreement, dated March 25, 2024 (the “CEO Agreements”). As a result of Mr. Lazar’s resignation in connection with the closing of the Transaction, on August 2, 2024, the Company issued to Mr. Lazar 440,028 shares of Common Stock, at a price of $3.03 per share of Common Stock, in lieu and settlement of the $1,333,284.84 owed by the Company to Mr. Lazar pursuant to the CEO Agreements. The issuance of such shares of Common Stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

     

    Item 5.01 Changes in Control of Registrant.

     

    The information set forth in Item 3.02 of this Current Report on Form 8-K (the “Form 8-K”) is incorporated into this Item 5.01 by reference.

     

    At the closing of the Transaction, Mr. Lazar transferred 550,000 shares of Series E Stock and his right to purchase an additional 2,450,000 shares of Series E Stock to AEI Capital Ltd. (the “Purchaser”) for $2,550,000, of which $500,000 will be retained by the Purchaser and paid to Mr. Lazar following the completion of Mr. Lazar’s continued employment with the Company for a period of sixty days. As a result of such transfer, along with an additional funding by the Purchaser of $200,000 in exchange for 200,000 shares of Series E Stock on August 1, 2024, as of August 2, 2024, AEI Capital Ltd. holds approximately 49% of the outstanding voting securities of the Company on an as-converted to Common Stock basis and, upon acquisition of the remaining 2,250,000 shares of Series E Stock, would hold approximately 80% of the outstanding voting securities of the Company on an as-converted to Common Stock basis. In connection with the consummation of the Transaction, Mr. Lazar resigned as Chief Executive Officer, Chairman and Director of the Company effective on August 2, 2024, and agreed to appoint a designee of the Purchaser as Chief Executive Officer, Chairman and Director of the Company. Mr. Lazar also agreed to continue his services to the Company in the role of President for a period of at least sixty days following the consummation of the Transaction.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    The information set forth in Items 3.02 and 5.01 of this Form 8-K is incorporated into this Item 5.02 by reference.

     

    In connection with the Transaction, on July 29, 2024, each of Avraham Ben-Tzvi, Matthew C. McMurdo and David Natan delivered notice of their resignation as a member of the Board and all committees thereof effective and contingent the successful consummation of the Transaction, the receipt by such directors of all amounts owed by the Company to such directors pursuant to the Director Agreement, dated March 25, 2024, entered into by each such director with the Company and the satisfaction of certain other conditions. Such resignations from the Board became effective on August 2, 2024 and were not a result of a disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices or any other matter.

     

    As described in Item 3.02 and 5.01 of this Form 8-K, in connection with the consummation of the Transaction, Mr. Lazar resigned from his positions as Chief Executive Officer, Chairman and Director of the Company effective August 2, 2024.

     

    Also in connection with the consummation of the Transaction, on August 2, 2024, the Board appointed John Tan, the designee of the Purchaser as Chief Executive Officer, Chairman and Director of the Company. The initial term as director for Mr. Tan will expire at the Company’s 2024 annual meeting of stockholders. At the time of election, Mr. Tan was not appointed to any committees of the Board.

     

    1

     

     

    Mr. Tan, 34, based in Kuala Lumpur, Malaysia, brings extensive expertise as a corporate strategist and private equity investor with significant legal experience in local and cross-border corporate mergers and acquisitions, corporate joint ventures and strategic alliances, foreign investment, private equity and venture capital deals, private fund establishment and structuring for private equity fund and venture capital funds, project financing, structuring of investment deals for high net-worth family offices, strategic structuring of business deals, and property transactions for both corporate and individual clients.

     

    Since January 2015, Mr. Tan has served as Chairman and CEO of AEI Capital Group headquartered in Kuala Lumpur, Malaysia with satellite offices in Singapore and Hong Kong, where he leads the Asia-Pacific-focused private equity investment group with AUM exceeding USD $500 million with the support of a seasoned team backed by diverse experience in more than 100 M&A transactions, exceeding 50 private equity deals and above 20 IPO exercises in major financial centers such as New York, Hong Kong, Singapore, Sydney and Kuala Lumpur. AEI Capital Group specializes in late-stage, pre-IPO investments, merger and acquisition/joint venture transactions, private equity/venture capital deals, private investment in public equity (PIPE), hedge fund portfolio, private fund structuring, and buy-out of high growth small and medium-sized enterprises and tech ventures, with preferred exit via IPO on global stock exchanges such as HKEX, ASX and NASDAQ. AEI Capital Group received the award of Best Private Equity Firm (East Asia) in Fund Awards 2021 granted by Wealth & Finance International (WFI).

     

    Since January 2020, Mr. Tan has served as co-President, Investment Banking Services Group at European Credit Investment Bank Ltd. where he leads its offshore investment banking services group to serve small-mid cap listed companies across Asia Pacific whose capital market needs are still mostly underserved by onshore investment banks and global institutional investors. Mr. Tan has served on the board of directors of various high growth companies across Asia Pacific and acted as the board advisor to various public listed companies across Asia Pacific.

     

    Earlier in his career, Mr. Tan specialized in mergers and acquisitions, capital markets and private equity as a common law-qualified cross-border corporate lawyer at Rajah and Tann Singapore LLP, the largest law firm in the ASEAN region, headquartered in Singapore, with affiliate offices in Cambodia, China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand and Vietnam, and founded in 1976. Mr. Tan also served as the regional counsel for a Fortune 100 Company in charge of the ASEAN and South Asia regions. Mr. Tan has received the honor of Global Innovator Award 2018 in Finance and Investment Category by Global SME Alliance, United Nations due to his significant contribution on ASEAN-plus-China One-Belt-One-Road private equity investment thesis. Mr. Tan spoke as a Panel Speaker in the Global SME Summit alongside with global leaders such as France’s ex-Prime Minister Mr. Jean-Pierre Raffarin and China’s ex-Vice Premier Mdm. Wu Gui Xian. Mr. Tan completed his Master of Business Administration (MBA) Essentials Programme at the London School of Economics and Political Science (LSE), with an Executive Program completed at the University of Oxford on Blockchain Strategy. He also completed his Postgrad Executive Programme in Alternative Investments at Harvard University.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Employment Agreement, dated April 11, 2024, by the Company and David Lazar (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on April 16, 2024).
    10.2   Form of Director Agreement (incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed on March 29, 2024).
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: August 2, 2024 OpGen, Inc.
         
      By: /s/ John Tan Honjian
        Name: John Tan Honjian
        Title: Chairman and Chief Executive Officer

     

    3

    Get the next $OPGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    12/10/24 12:32:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    10/8/24 6:51:09 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

    ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

    5/24/24 4:04:59 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Announced 1-for-10 Reverse Stock Split

    ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

    5/16/24 7:00:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by OpGen Inc.

    DEF 14A - OPGEN INC (0001293818) (Filer)

    2/6/26 1:05:05 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by OpGen Inc.

    PRE 14A - OPGEN INC (0001293818) (Filer)

    1/26/26 5:25:46 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)

    3 - OPGEN INC (0001293818) (Issuer)

    12/10/25 9:08:45 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    4/30/25 4:32:10 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright resumed coverage on OpGen with a new price target

    HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

    3/15/21 7:37:07 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/8/21 8:22:12 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/2/21 10:53:18 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OpGen Inc.

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    8/1/24 5:25:39 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/25/24 5:43:11 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/8/24 4:05:12 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Financials

    Live finance-specific insights

    View All

    OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

    8/10/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

    ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

    8/3/23 7:30:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

    5/15/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care